Multiple myeloma, also known as Kahler's disease, is a type of blood cancer. There's no cure, but treatments can slow its spread and sometimes make symptoms go away. A type of white blood cell called a plasma c
There are three major types of blood cancer: Leukemia Lymphoma Myeloma These cancers cause your bone marrow and lymphatic system to make blood cells that don't work as well as they should. They all affect different types of white blood cells, and they act in different ways. ...
The most common adverse reactions observed in at least 50% of patients with multiple myeloma treated with EVOMELA were neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased, platelet count decreased, diarrhea, nausea, fatigue, hypokalemia, anemia, and vomiting. ...
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood ...
The most common adverse reactions observed in at least 50% of patients with multiple myeloma treated with EVOMELA were neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased, platelet count decreased, diarrhea, nausea, fatigue, hypokalemia, anemia, and vomiting. ...
Revealing The Role Of DNA Methylation In Multiple Myeloma Blood CancerSteve Yozwiak
The Pharmacy Times® Multiple Myeloma Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that forms in a type of white blood cell.
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables inclu
The introduction of high-dose therapy followed by autologous blood stem cell transplantation (HDT/ABSCT) and the novel agents led to continuously improving survival in multiple myeloma (MM)1,2. However, the majority of MM patients ultimately relapses or progresses, and deceases of disease related...
Bortezomib, a...Multiple Myeloma By Julia Cipriano, MS / September 2024 Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health A retrospective cohort study published in Blood Cancer Journal by Gasoyan et al revealed discrepancies between the timing of the initiation...